Premium
Response of lymphoid leukemia L1210 in mice to implantable sustained release cytosine arabinoside capsules
Author(s) -
Fu J. C.,
Khwaja T.,
Moyer D. L.,
Cummings L.,
Varvan J.,
Elshire D.
Publication year - 1978
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930100102
Subject(s) - medicine , in vivo , drug , cytarabine , capsule , leukemia , cytosine , pharmacology , implant , in vitro , immunology , surgery , chemistry , biology , biochemistry , dna , botany , microbiology and biotechnology
The lifespan of BDF mice with ascitic L1210 leukemia is more than doubled when they are treated with a single subcutaneously or intraperitoneally implanted sustained release cytosine arabinoside capsule. These capsules are drug‐polymer composites, with dimensions of 1.0 cm in diameter and 0.15 cm in thickness, and a drug content of 17 ± 3 mg each. Blank silicone rubber discs implanted intra‐peritoneally or subcutaneously in the leukemic mice produced no beneficial effects. Control healthy mice receiving the ARA‐C releasing capsules continued to live with no obvious signs of drug toxicity. In vitro release of ARA‐C from the discs was measured. Drug release was maintained above 20 micro‐grams per day for more than 35 days. ARA‐C extracted from discs recovered from implant studies showed that less than 16% of the total drug content was released in vivo.